Haematology
Publications
Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol Med 2006;125:93-106.
Branford S, Hughes T. Diagnosis and monitoring of chronic myeloid leukaemia by qualitative and quantitative RT-PCR. Methods Mol Med 2006;125:69-92.
Dewar AL, Farrugia AN, Condina MR, To LB, Hughes TP, Vernon-Roberts B, Zannettino AC. Imatinib as a potential anti-resorptive therapy for bone disease. Blood 2006;107(11):4334-7.
Guthridge MA, Powell JA, Barry EF, Stomski FC, McClure BJ, Ramshaw H, Felquer FA, Dottore M, Thomas DT, To LB, Begley CG, Lopez AF. Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO J 2006;25(3):479-89.
Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Rev 2006;20:29-41.
Keefe D, Lees J, Horvath N. Palifermin for oral mucositis in the high-dose chemotherapy and stem cell tansplant setting: the Royal Adelaide Hospital Cancer Centre experience. Support Care Cancer 2006.
McRae SJ, Ginsberg JS. Update in the diagnosis of deep-vein thrombosis and pulmonary embolus. Curr Opin Anaesthesiol 2006;19(1):44-51.
Martin SK, Dewar AL, Farrugia AN, Horvath N, Gronthos S, To LB, Zannettino ACW. Tumour angiogenesis is associated with plasma levels of SDF-1a in patients with multiple myeloma. Clin Cancer Res 2006 (in press).
Mitchell E, Thomas D, Burnet R. Testosterone improves motor function in Parkinson’s Disease. J Clin Neurosci 2006;13(1):133-6.
Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL. Leukaemia 2006;20(4):664-670.
Stewart GW, Lloyd JV, Pegel K. Mediterranean stomatocytosis/macrothrombocytopenia: Update from Adelaide, Australia. British Journal of Haematology 2006;132:651-661.
Tran H, McRae S, Ginsberg J. Anticoagulant treatment of deep vein thrombosis and pulmonary embolism. Clin Geriatr Med 2006;22(1):113-34.
White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. OCT-1 mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107); reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 2006;108(2):697-704.
Al Muslahi M, Teague M, Lee SH, Roberts M. Multiple myeloma simulating Gaucher's disease. British Journal of Haematology 134:123, 2006.
Butcher CM, Hutton JF, Hahn U, To LB, Bardy P, Lewis I, D’Andrea R. Cellular origin and lineage specificity of the JAK2V617F allele in polycythaemia vera. Blood (in press).
Davis K, Hui CH, Quested B. Transfusing safely: a 2006 guide for nurses. Australian Nursing Journal 13:17-20, 2005-2006.
Hutton JF, Rozendov V, Khor FSL, D’Andrea R, Lewis ID. BMP4 contributes to the maintenance of primitive cord blood hematopoietic progenitors in an ex-vivo stroma non-contact co-culture system. Stem Cells and Development (in press).
Stewart GW, Lloyd J, Pegel K. Mediterranean stomatocytosis / macrothrombocytopenia: update from Adelaide, Australia. British Journal of Haematology 132:660-661, 2006.
Grigg AP, Shuttleworth P, Reynolds J, Schwarer A P, Szer J, Bradstock K, Hui CH, Herrmann R, and Ebeling PR. Pamidronate reduces bone loos after allogeneic stem cell transplantation. J Clin Endocrinol Metab 2006; 91: 3835-3843.
Hui CH, Hughes T. Autologous stem cell collection and autograft for patients with chronic myeloid leukaemia (CML) in the era of ABL kinase inhibitors – back to the bench. Leukemia Lymphoma 2006; 47: 1721-1723. (Invited editorial)
Sia H, Mangos H, Horvath N, Lee HK, Hughes T, To LB, Bardy P, Hui CH. Daclizumab has poor efficacy in steroid-refractory severe acute graft versus host disease: A single centre experience with 12 allograft patients. EHA, Amsterdam 2006 (Abstract)
Hui CH, Horvath N, Lewis I, To LB, Szabo F. South Australian Myelodysplastic syndromes (MDS) Database. HSANZ Annual meeting, Hobart 2006
Hughes TP, Deininger MW, Hochhaus A, Branford S, Radich JP, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman J. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors – Review and recommendations for ‘harmonizing’ current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006. 108(1):28-37
Grigg A, Hughes TP. Role of allogeneic stem cell transplantation for adult chronic myeloid leukaemia in the imatinib era. Biol Blood Marrow Transplant 2006.
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes TP, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann. Evolving concepts in the management of chronic myeloid leukaemia: recommendations from an expert panel on behalf of the European Leukaemia Net. Blood 2006. 108(6):1809-1820.
Branford S, Cross NC, Hochhaus A, Radich J, Saglio, Kaeda J, Goldman J, Hughes T. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukaemia 2006. 20(11):1925-30.
Luke C, Nguyen AM, To LB, Seshadri R, Hughes TP, Bardy P, Colbeck M, Buranyi-Trevarton D, McMellon M, Roder D. Myeloid leukaemia and treatment and survival – the South Australian Experience 1977 – 2002. Asian Pacific J Cancer Prev 2006. (7): 227-233
Druker B, Guilhot F, O’Brien S, Gathman I, Kantasrjian H, Gattermann N, Deininger M, Silver R, Goldman J, Stone R, Cervantes F, Hochhaus A, Powell B, Gabrilove J, Rousselot P, Reiffers J, Cornelissen J, Hughes TP, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen J, Radich J, Simonsson B, Taylor K, Baccarani M, So C, Letvak L, Larson R. Five-year follow up of patients receiving Imatinib for chronic myeloid leukaemia. New England Journal of Medicine. 2006:355:2407-17.
Hochhaus A, Kantarjian M, Baccarani M, Lipton J, Apperley J, Duker B, Facon T, Goldberg S, Cervantes F, Niederwieser D, Silver R, Stone R, Hughes TP, Muller M, Ezzeddine R, Countouriostis A, Shah N. Dasatinib induces notable haematologic and cytogenetic responses in chronic phase chronic myeloid leukaemia after failure of imatinib therapy. Blood 2006. 10:1182